FDA approves Iroko's pain drug Zorvolex
This article was originally published in Scrip
Executive Summary
The US FDA granted approval for Iroko Pharmaceuticals to market Zorvolex (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), as a treatment for mild-to-moderate acute pain in adults.